TY - JOUR
T1 - European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1
T2 - Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence
AU - Nambiar, Arjun K.
AU - Arlandis, Salvador
AU - Bø, Kari
AU - Cobussen-Boekhorst, Hanny
AU - Costantini, Elisabetta
AU - de Heide, Monica
AU - Farag, Fawzy
AU - Groen, Jan
AU - Karavitakis, Markos
AU - Lapitan, Marie Carmela
AU - Manso, Margarida
AU - Arteaga, Serenella Monagas
AU - Riogh, Aisling Nic An
AU - O'Connor, Eabhann
AU - Omar, Muhammad Imran
AU - Peyronnet, Benoit
AU - Phé, Veronique
AU - Sakalis, Vasileios I.
AU - Sihra, Néha
AU - Tzelves, Lazaros
AU - van Poelgeest-Pomfret, Mary Lynne
AU - van den Bos, Tine W.L.
AU - van der Vaart, Huub
AU - Harding, Christopher K.
N1 - Funding Information:
Financial disclosures: Arjun K. Nambiar certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christopher K. Harding is a company consultant for Teleflex Medical; has received speaker honoraria from Astellas, Allergan, and Medtronic; has participated in clinical trials by Medtronic; has received fellowship and travel grants from Medtronic; and has received research support from the National Institute for Health Research and The Urological Foundation. Marie Carmela Lapitan has received speaker honoraria from Astellas, AstraZeneca, and GSK. Salvador Arlandis has received company speaker honoraria from Astellas Pharma S.A., Bayer Hispania S.L., and Lacer-Holliste; has received honoraria for consultation from Presurgy S.L., Boston Scientific Europe, and Coloplast Productos Medicos; has participated in clinical trials by GlaxoSmithKline, Astellas, Ipsen, and Urovant; has received travel grants from Astellas Pharma S.A., WellSpect, Lacer, and Rovi; and was a company consultant for Lacer Laboratories. Elisabetta Costantini has received research support from S&R Farmaceutici. Jan Groen has participated in clinical trials by Neuspera Medical Inc. Veronique Phé has received speaker honoraria from Medtronic and Viatris and is a company consultant for Allergan and Coloplast. Huub van der Vaart has ownership of a patent with Ligalli B.V., is a director of Berman Clinics, receives royalties from NVOG, is participating in clinical trials by UroGyn, and receives research support from ZonMw and NWO-TTW. Benoit Peyronnet is a company consultant for Boston Scientific. Lazaros Tzelves receives research support from the National and Kapodistrian University of Athens and the ASCAPE Project and is participating in a clinical trial by the ASCAPE Project and received. The remaining authors have nothing to disclose.
PY - 2022/2/23
Y1 - 2022/2/23
N2 - Context: Female lower urinary tract symptoms (LUTS) are a common presentation in urological practice. Thus far, only a limited number of female LUTS conditions have been included in the European Association of Urology (EAU) guidelines compendium. The new non-neurogenic female LUTS guideline expands the remit to include these symptoms and conditions. Objective: To summarise the diagnostic section of the non-neurogenic female LUTS guideline and the management of female overactive bladder (OAB), stress urinary incontinence (SUI), and mixed urinary incontinence (MUI). Evidence acquisition: New literature searches were carried out in September 2021 and evidence synthesis was conducted using the modified GRADE criteria as outlined for all EAU guidelines. A new systematic review (SR) on OAB was carried out by the panel for the purposes of this guideline. Evidence synthesis: The important considerations for informing guideline recommendations are presented, along with a summary of all the guideline recommendations. Conclusions: Non-neurogenic female LUTS are an important cause of urological dysfunction. Initial evaluation, diagnosis, and management should be carried out in a structured and logical fashion based on the best available evidence. This guideline serves to present this evidence to health care providers in an easily accessible and digestible format. Patient summary: This report summarises the main recommendations from the European Association of Urology guideline on symptoms and diseases of the female lower urinary tract (bladder and urethra) not associated with neurological disease. We cover recommendations related to diagnosis of these conditions, as well as the treatment of overactive bladder, stress urinary incontinence, and mixed urinary incontinence.
AB - Context: Female lower urinary tract symptoms (LUTS) are a common presentation in urological practice. Thus far, only a limited number of female LUTS conditions have been included in the European Association of Urology (EAU) guidelines compendium. The new non-neurogenic female LUTS guideline expands the remit to include these symptoms and conditions. Objective: To summarise the diagnostic section of the non-neurogenic female LUTS guideline and the management of female overactive bladder (OAB), stress urinary incontinence (SUI), and mixed urinary incontinence (MUI). Evidence acquisition: New literature searches were carried out in September 2021 and evidence synthesis was conducted using the modified GRADE criteria as outlined for all EAU guidelines. A new systematic review (SR) on OAB was carried out by the panel for the purposes of this guideline. Evidence synthesis: The important considerations for informing guideline recommendations are presented, along with a summary of all the guideline recommendations. Conclusions: Non-neurogenic female LUTS are an important cause of urological dysfunction. Initial evaluation, diagnosis, and management should be carried out in a structured and logical fashion based on the best available evidence. This guideline serves to present this evidence to health care providers in an easily accessible and digestible format. Patient summary: This report summarises the main recommendations from the European Association of Urology guideline on symptoms and diseases of the female lower urinary tract (bladder and urethra) not associated with neurological disease. We cover recommendations related to diagnosis of these conditions, as well as the treatment of overactive bladder, stress urinary incontinence, and mixed urinary incontinence.
KW - Female lower urinary tracts symptoms
KW - diagnostics
KW - overactive bladder
KW - urinary incontinence
KW - stress urinary incontinence
KW - mixed urinary incontinence
KW - conservative management
KW - pharmacologic management
KW - surgical management
KW - EAU Guidelines
UR - http://www.scopus.com/inward/record.url?scp=85125126549&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2022.01.045
DO - 10.1016/j.eururo.2022.01.045
M3 - Article
AN - SCOPUS:85125126549
JO - European Urology
JF - European Urology
SN - 0302-2838
ER -